Luminex Corporation Receives Research Grant from the Department of the Army

Research Will Employ the Company's Chip-Scale xMAP Technology 


AUSTIN, Texas, July 25  /PRNewswire-FirstCall/ -- Luminex Corporation (NASDAQ:LMNX), a leading multiplex solution developer, today announced that the Company has received a research grant from the Defense Advanced Research Projects Agency (DARPA), which will be administered through the Department of the Army's U.S. Army Research Office. The $300,000 research grant covers a 12- month period and will focus on developing the Company's emerging chip-scale xMAP(R) technology for bio-defense applications. The chip-scale concept is a radically new approach that leverages Luminex's proven flagship xMAP technology, which is a bead-based flow cytometry solution for multiplexing biological assays, to perform the detection of bio-pathogens on the scale of a micro-chip.

Dr. John Carrano, vice president of research and development of Luminex Corporation, stated, "A successful and practical solution for bio-sensors to combat terrorism will require a compact, and relatively inexpensive detector capable of doing species identification with high sensitivity and specificity; that is precisely the goal of the chip-scale xMAP technology project."

Commenting on the announcement, Patrick Balthrop, president and chief executive officer of Luminex Corporation, added, "We are very pleased to have been awarded this initial grant by DARPA, which will enable us to leverage our state-of-the-art technology and increase our market awareness within the government sector. This opportunity will also make Luminex more competitive for future research grants that utilize our systems and technology."

About Luminex

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex's ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company's operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading "Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

  Contact:  Harriss T. Currie
            Vice President, Finance and Chief Financial Officer
            512-219-8020
            

DATASOURCE: Luminex Corporation



CONTACT:  Harriss T. Currie, Vice President, Finance and Chief Financial

Officer of Luminex Corporation, [phone], or  



Web site:  http://www.luminexcorp.com/ 

Copyright